Oasis Submits Shareholder Proposals to Kobayashi Pharmaceutical for 2026 AGM
View original at finance.yahoo.comOasis Submits Shareholder Proposals to Kobayashi Pharmaceutical for 2026 AGM (Securities Code: 4967 JT) *Oasis urges Kobayashi Pharma shareholders to vote FOR a highly qualified, independent statutory auditor candidate *Oasis urges Kobayashi Pharma shareholders to vote FOR Oasis’s proposals to change the Articles of In…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Akihiro Kobayashi has taken on additional responsibilities beyond victim compensation, such as serving on the executive Compensation Committee, deviating from the original reasons for his selection.
80% confidenceCorporate governance reforms at Kobayashi Pharmaceutical are not yet complete, with the company continuing to be overly influenced by the founding family.
80% confidenceOasis's proposals aim to reduce founding family influence through multiple layers of measures that strengthen corporate governance in line with management's wishes.
80% confidenceOasis is the largest shareholder of Kobayashi Pharmaceutical, beneficially owning over 13.1% of the company.
80% confidenceAkihiro Kobayashi was one of the root causes of the Beni-Koji incident and continues to exert influence on Kobayashi Pharmaceutical, preventing the company from breaking free from founding family influences.
80% confidenceYoshiro Katae's expertise in crisis management and compliance was not meaningfully applied, contributing to the escalation of harm in the Beni-Koji incident.
80% confidenceKobayashi Pharmaceutical has not yet been able to fully break free from the influences of the Kobayashi Family, who were one of the major causes of the slow response to the Beni-Koji incident.
80% confidenceHitoshi Kawaguchi will provide particularly valuable oversight regarding management's execution of duties concerning establishment and operation of internal control systems.
80% confidenceImproved quality assurance measures have not been fully implemented at Kobayashi Pharmaceutical, as evident from a recent product recall.
80% confidence